Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.71 Million EUR | -604.83% |
| 2022 | 3.14 Million EUR | 75.59% |
| 2021 | 1.79 Million EUR | 280.93% |
| 2020 | 470.47 Thousand EUR | 184.87% |
| 2019 | -554.33 Thousand EUR | -855.47% |
| 2018 | 73.37 Thousand EUR | 176.93% |
| 2017 | -95.37 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 483 Thousand EUR | 110.79% |
| 2024 Q2 | -4.63 Million EUR | 4.35% |
| 2023 Q3 | 340 Thousand EUR | -31.73% |
| 2023 Q1 | 583 Thousand EUR | -28.28% |
| 2023 Q4 | -4.47 Million EUR | -1416.62% |
| 2023 FY | -15.88 Million EUR | -604.83% |
| 2023 Q2 | 498 Thousand EUR | -14.58% |
| 2022 Q3 | 815 Thousand EUR | -0.61% |
| 2022 FY | 3.14 Million EUR | 75.59% |
| 2022 Q4 | 812.88 Thousand EUR | -0.26% |
| 2022 Q2 | 820 Thousand EUR | 17.31% |
| 2022 Q1 | 699 Thousand EUR | 14.18% |
| 2021 Q1 | 243 Thousand EUR | 80.71% |
| 2021 Q3 | 418 Thousand EUR | -19.31% |
| 2021 Q4 | 612.17 Thousand EUR | 46.45% |
| 2021 Q2 | 518 Thousand EUR | 113.17% |
| 2021 FY | 1.79 Million EUR | 280.93% |
| 2020 FY | 470.47 Thousand EUR | 184.87% |
| 2020 Q4 | 134.47 Thousand EUR | 33.14% |
| 2020 Q3 | 101 Thousand EUR | -29.86% |
| 2020 Q2 | 144 Thousand EUR | 60.0% |
| 2020 Q1 | 90 Thousand EUR | 155.1% |
| 2019 Q1 | -55 Thousand EUR | 0.0% |
| 2019 Q4 | -163.33 Thousand EUR | -341.45% |
| 2019 FY | -554.33 Thousand EUR | -855.47% |
| 2019 Q3 | -37 Thousand EUR | 58.89% |
| 2019 Q2 | -90 Thousand EUR | -63.64% |
| 2018 FY | 73.37 Thousand EUR | 176.93% |
| 2017 FY | -95.37 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biohit Oyj | 3.97 Million EUR | 56.805% |
| Herantis Pharma Oyj | - EUR | -Infinity% |